Selective KRAS G12C Inhibitor MK-1084 as Monotherapy, in Combination With Pembrolizumab: A Phase 1 Dose-Escalation Study
Adagrasib Plus Cetuximab Shows Promise for Patients With KRAS-Mutated Colorectal Cancer
LAG-3 and PD-1 Inhibitors for Esophageal and Gastroesophageal Junction Cancer: A Phase Ib Trial